Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive tags : For save search
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
Published: 2024-04-25 (Crawled : 08:00) - biospace.com/
IBRX | $4.82 -12.2% -14.02% 7.4M
|
Manufacturing
| Email alert
Add to watchlist
fda anktiva lung positive cancer cell for meeting results
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
ACRV | $9.5 -3.26% -3.81% 160K
|
| Email alert
Add to watchlist
acr-368 positive pipeline for program therapeutics today
BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior ExchangeStrategic Audit Completion Set to Enhance BioStem Technologies' Market Position and Shareholder Value
Published: 2024-04-24 (Crawled : 15:00) - biospace.com/
BSEM | $9.355 1.24% -38.71% 24K
|
n/a
|
| O: 0.0%
H: 1.73%
C: 1.3%
for set market
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
GANX | $3.19 -5.9% -7.28% 150K
|
Professional, Scientific, and T...
|
| O: 4.42%
H: 3.11%
C: -9.89%
gt-0228 disease positive for parkinson’s trial therapeutics therapy results
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
INVA | $15.16 -0.07% -0.13% 530K
|
Health Technology
|
| O: 1.03%
H: 0.72%
C: -0.13%
positive treatment global for
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published: 2024-04-24 (Crawled : 05:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.36%
H: 0.05%
C: -0.15%
malaria positive treatment for novartis
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
NBIX | News 4 | $138.97 -0.8% -0.85% 930K
|
Health Technology
|
| O: 5.49%
H: 2.84%
C: -0.65%
nbi-1065 positive for
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
SILO | $1.88 5.62% 6.32% 380K
|
Finance and Insurance
|
| O: 9.18%
H: 0.47%
C: -16.82%
pharma positive treatment for results
Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K
|
Health Technology
|
| O: -0.4%
H: 3.01%
C: 2.94%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.83%
H: 1.35%
C: 1.2%
ABT | News | $106.89 -0.65% 0.07% 4.2M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
first treatment for
Zscaler Positioned as a Leader in the 2024 Gartner® Magic Quadrant™ for Security Service Edge (SSE) for Third Straight Year
Published: 2024-04-18 (Crawled : 19:00) - globenewswire.com
IT | $451.06 0.18% 0.0% 280K
|
Commercial Services
|
| O: 0.42%
H: 0.26%
C: -2.25%
ZS | $177.46 0.31% 0.31% 1.2M
|
Technology Services
|
| O: -3.08%
H: 0.11%
C: -1.62%
gartner service year security for
LinkShadow is positioned as a Representative Vendor in the 2024 Gartner® Market Guide for Network Detection and Response (NDR)
Published: 2024-04-18 (Crawled : 14:00) - prnewswire.com
IT | $451.06 0.18% 0.0% 280K
|
Commercial Services
|
| O: -0.15%
H: 0.0%
C: 0.0%
gartner for network response market
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | $6.72 -2.04% -1.63% 67K
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $41.9 -0.21% -0.29% 630K
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
OCUL | News | $4.645 -7.1% -7.64% 4M
|
Health Technology
|
| O: -5.78%
H: 0.0%
C: 0.0%
ocular positive for topline diabetic
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | $2.59 3.19% 3.09% 1.4M
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
tacti-004 lung positive cancer cell for trial
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
PTPI | $0.6344 -6.72% -7.1% 180K
|
|
| O: 9.85%
H: 4.63%
C: -18.04%
fda positive pharmaceuticals for technology response
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Published: 2024-04-16 (Crawled : 13:00) - globenewswire.com
MYGN | $18.63 0.16% 0.05% 480K
|
Health Technology
|
| O: -2.61%
H: 0.0%
C: 0.0%
prequel positive for study
Blue Biofuels Initiates Engineering and Design for Their CTS Commercial Plant Positioned to Produce Ethanol from Cellulosic Materials
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
BIOF | $0.0975 10.29% 34.16% 23K
|
Information
|
| O: 0.36%
H: 6.02%
C: 5.9%
for commercial design blue
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.0 0.5% 120K
|
Health Technology
|
| O: 64.34%
H: 4.82%
C: -18.67%
fxr314 metabolic liver positive for results
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
OCGN | News 4 | $1.18 -5.6% -6.84% 7.2M
|
Health Technology
|
| O: 2.92%
H: 3.41%
C: 2.27%
ocu400 approval positive for therapy
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.